New #CochraneEvidence: Short-acting erythropoiesis-stimulating agents for anaemia in predialysis patients https://t.co/IFKGmI01BZ https://t.co/hUO5p0E22J
RT @KFSHRC_Research: Short-acting erythropoiesis-stimulating agents for #anaemia in #predialysis patients https://t.co/U6aees6TiH https://t…
RT @KFSHRC_Research: Short-acting erythropoiesis-stimulating agents for #anaemia in #predialysis patients https://t.co/U6aees6TiH https://t…
RT @KFSHRC_Research: Short-acting erythropoiesis-stimulating agents for #anaemia in #predialysis patients https://t.co/U6aees6TiH https://t…
Short-acting erythropoiesis-stimulating agents for #anaemia in #predialysis patients https://t.co/U6aees6TiH https://t.co/23cIIKttRR
Uso EPO Revision https://t.co/dafgjzBRjr
RT @CochraneKidney: New review: Shorter acting epoetins given every 2 to 4 wks results in similar #anemia correction as every 1 or 2 wks ht…
RT @CochraneKidney: New review: Shorter acting epoetins given every 2 to 4 wks results in similar #anemia correction as every 1 or 2 wks ht…
RT @CochraneKidney: New review: Shorter acting epoetins given every 2 to 4 wks results in similar #anemia correction as every 1 or 2 wks ht…
Short-acting erythropoiesis agents in chronic kidney disease patients not requiring dialysis https://t.co/Yeoz3kXz83
RT @CochraneKidney: New review: Shorter acting epoetins given every 2 to 4 wks results in similar #anemia correction as every 1 or 2 wks ht…
New review: Shorter acting epoetins given every 2 to 4 wks results in similar #anemia correction as every 1 or 2 wks https://t.co/rmHw5hL0nL